Targeting the Fas/Fas ligand pathway in cancer.

O'Brien, Darren I; Nally, Ken; Kelly, Raymond G; O'Connor, Terrence M; Shanahan, Fergus; O'Connell, Joe

O'Brien, Darren I; Nally, Ken; Kelly, Raymond G; O'Connor, Terrence M; Shanahan, Fergus; O'Connell, Joe.

Afiliación

O'Brien DI; Department of Medicine, NUIC, Clinical Sciences Building, University Hospital, Cork, Ireland.

Expert Opin Ther Targets ; 9(5): 1031-44, 2005 Oct.

Article en En | MEDLINE | ID: mdl-16185156

RESUMEN

Fas is a transmembrane receptor that can induce apoptosis after cross-linking with either agonistic antibodies or with Fas ligand (FasL). Although originally described as an important regulator of peripheral immune homeostasis, accumulating evidence suggests that the Fas/FasL system plays an important role in tumour development. In addition to its proapoptotic functions, accumulating evidence demonstrates that Fas can activate numerous nonapoptotic signalling pathways, and that activation of these pathways can result in increased tumourigenicity and metastasis. This review summarises the current understanding of the Fas/FasL system in tumorigenesis and discusses attempts to utilise the Fas/FasL system in the treatment of cancer.

Asunto(s)

Antineoplásicos/farmacología; Proteína Ligando Fas/metabolismo; Neoplasias/tratamiento farmacológico; Receptor fas/metabolismo; Antineoplásicos/uso terapéutico; Humanos; Neoplasias/metabolismo

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor fas / Proteína Ligando Fas / Neoplasias / Antineoplásicos Límite: Humans Idioma: En Revista: Expert Opin Ther Targets Asunto de la revista: TERAPEUTICA Año: 2005 Tipo del documento: Article País de afiliación: Irlanda Pais de publicación: Reino Unido

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links